NewsRoom Articles - Page 8 of 251

MondayAug 12, 2024 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Q3 2024 Financial Results; Offers a Roadmap for its Key GLP-1 Study Program

The company provided updates for its study programs for 2024, with a focus on its glucagon-like peptide-1 (“GLP-1”) agonist research program, targeting a significant step up in addressing worldwide diabetes and obesity, a tremendous market Lexaria has its Human Pilot Study #3 lined up, as well as its chronic dosing human study, both studies will begin dosing later this year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). Of note was growth in cash and marketable securities from $1.5 million during…

FridayAug 09, 2024 10:00 am

Hemp Farmers Say Crop Can Be Good Entry Point for New Growers

Data from the South Dakota Industrial Hemp Association estimates that there are more than 3,000 acres of hemp being grown in the state this year. While this is a substantial amount, it has been overshadowed by the planting of other crops. This year, farmers in South Dakota planted 5.1 million acres and 6.1 million acres of soybeans and corn, respectively. From this, we can see that hemp has a long way to go as a cash crop before it can compete with crops such as soybean, corn, wheat and sorghum. Despite this, the president of the South Dakota Industrial Hemp…

ThursdayAug 08, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments

Lexaria, a global innovator in drug delivery platforms, is exploring alternatives to traditional diabetes and obesity management through its patented DehydraTECH(TM) technology to potentially enhance oral ingestion vs. injection treatment of GLP-1 drugs The company has made significant strides pairing their bioavailability enhancing DehydraTECH with glucagon-like peptide-1 (“GLP-1”) drugs used for treatment of diabetes and obesity Projections are that by 2030 over 54.9 of Americans could have diabetes, and that by 2045 one in eight adults globally will be living with the condition According to the International Diabetes Federation Diabetes Atlas of 2021, 10.5% of adults aged between 20 and…

WednesdayAug 07, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”

The report explores the growth, competition, and consumer trends, for lesser known cannabinoids The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the industry product landscape is set to evolve With the increasing acceptance of cannabis use in society, the popularity of edibles—products containing cannabinoids that can be consumed as food or drink—has surged. While many consumers are familiar with edibles containing THC (tetrahydrocannabinol), known for its euphoric effects, or CBD (cannabidiol), recognized for its therapeutic benefits,…

TuesdayAug 06, 2024 10:00 am

New Study Says CBD Lotion Reduces UV Damage to Skin

New research has determined that applying lotion infused with CBD to one’s skin may be linked to a reduced risk of damage from ultraviolet (UV) rays. The research was carried out by a team of researchers from Northwestern University, George Washington University, the Center for Clinical and Cosmetic Research and the University of Miami. The researchers’ objective was to find out whether the antioxidant and anti-inflammatory properties of CBD could alleviate skin aging and cancer risks associated with exposure to the sun, particularly exposure to ultraviolet-A radiation. This is mainly because UV rays contribute to photocarcinogenesis and photoaging by generating…

ThursdayAug 01, 2024 10:00 am

EPA Gives Nonprofit $6.2M Grant to Promote Hemprete, Agriculture-Derived Building Materials

Last week, the Environmental Protection Agency (EPA) under the U.S. federal government awarded over $6 million in grants to the Hemp Building Institute. The nonprofit, which is based in Nashville, manufactures a material similar from hemp that is similar to concrete; the substance is known as hempcrete. The institute works with organizations that use and manufacture construction products. In total, Hemp Building Institute will be allocated $6,186,200 for the development of life-cycle assessments and environmental product declarations for biogenic materials, including materials manufactured from soy, hemp and straw bale. The awarded grant is part of a $160 million financing round…

WednesdayJul 31, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Study

Lexaria, a global innovator in drug delivery platforms, has released interim results from its WEIGHT-A24-1 animal study The study sought to explore the impact of its patented DehydraTECH technology on glucagon-like peptide-1 (“GLP-1”) drugs for the potential treatment of diabetes and weight loss, representing a major global market The first 28 days of dosing yielded positive results that Lexaria’s management described as “noteworthy” It also marked a significant milestone for the company and the first time it has used liraglutide in any of its GLP-1 studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery enhancement, just released interim…

TuesdayJul 30, 2024 10:00 am

Despite Industry Protests, Texas GOP Wants Intoxicating Hemp Banned

The consumable hemp industry in the state of Texas is valued at an estimated $8 billion. When legislators drafted a law to legalize hemp in 2019, they didn’t consider the fact that intoxicating hemp could find its way to the market. At the time of enactment, CBD was the most common compound derived from hemp. This compound is known for not inducing a high when ingested, and it possesses medicinal properties. However, the industry’s growth allowed for the proliferation of intoxicating hemp, which induces highs when consumed. Currently, intoxicating compounds derived from hemp that are made into products such as…

ThursdayJul 25, 2024 10:00 am

Supreme Court Ruling Could Set Precedent Regarding Hemp as RICO Case Review Concludes

The Supreme Court is expected to give a ruling on a case involving hemp. This is the first time since the 2018 Farm Bill was enacted that the court will be ruling on any hemp-related case. This farming measure federally legalized the sale and production of hemp and its derivatives. This bill distinguishes marijuana from hemp by categorizing hemp as cannabis that doesn’t contain more than 0.3% THC. THC is one of the two primary compounds found in marijuana plants, with the other being CBD. Unlike THC, however, CBD doesn’t induce a high when ingested. CBD is one of hemp’s…

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

News and publishing service for hemp related companies

Contact us: 512.354.7000